[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335530-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335530-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","urease-powered-nanomotor-containing-sting-agonist-for-bladder-cancer-immunotherapy","Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy","","Urease-powered nanomotors are developed to deliver a STING agonist into the bladder wall for immunotherapy of non-muscle invasive bladder cancer. Low delivery efficiency from intravesical injections is addressed by using a self-propelling system capable of efficient penetration and retention after instillation. In vitro motion characterization and in vivo swarming behavior are assessed, followed by evaluation of anti-tumor efficacy in female mouse bladder cancer models. Results show strong tumor inhibition (94.2%), CD8+ T-cell recruitment (11.2-fold vs PBS), and enhanced immune responses, with superior efficacy compared with BCG and pembrolizumab.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/urease-powered-nanomotor-containing-sting-agonist-for-bladder-cancer-immunotherapy/335530/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/urease-powered-nanomotor-containing-sting-agonist-for-bladder-cancer-immunotherapy/335530.png","ImageObject",300,407,{"name":42,"@type":43},"Quinn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is intravesical delivery difficult for bladder cancer immunotherapy?","Question",{"text":63,"@type":64},"Therapeutic agents have low delivery efficiency because frequent urination clears them and the urothelial glycosaminoglycan layer hinders penetration into the bladder wall.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the main goal of the urease-powered nanomotor in this study?",{"text":68,"@type":64},"To enable rapid and efficient delivery of a STING agonist into the bladder wall, improving activation of immune cells within the tumor environment.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the nanomotor perform compared with standard therapies?",{"text":72,"@type":64},"The STING agonist nanomotor shows stronger anti-tumor effects than BCG and the anti-PD-1 inhibitor pembrolizumab in a bladder cancer mouse model, including high tumor inhibition and enhanced CD8+ T-cell recruitment.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335530,1790491074,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":109,"preview_page_count":4},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article [https://doi.org/10.1038/s41467-024-54293-z](https://doi.org/10.1038/s41467-024-54293-z)  \nUrease-powered nanomotor containing STING agonist for bladder cancer immunotherapy  \nReceived: 23 March 2023  \n\n| Accepted: 6 November 2024 |\n| --- |\n| |\n| Check for updates |\n\nHyunsik Choi1,2,9, Seung-hwan Jeong 3,4,9, Cristina Simó Jordi Liop 5, Hye Sun Lee4, Tae Yeon Kim6, Cheol Kwak  \n5, Anna Bakenecker1, 3,4  \n,  \nGou Young Koh 7 , Samuel Sánchez 1,8  & Sei Kwang Hahn 2,6   \nMost non-muscle invasive bladder cancers have been treated by transurethral resection and following intravesical injection of immunotherapeutic agents. However, the delivery efﬁciency of therapeutic agents into bladder wall is low due to frequent urination, which leads to the failure of treatment with side effects. Here, we report a urease-powered nanomotor containing the agonist ofstimulatorofinterferon genes(STING)for the efﬁcient activation ofimmune cells in the bladder wall. After characterization, we perform in vitro motion analysis and assess in vivo swarming behaviors ofnanomotors. The intravesical instillation results in the effective penetration and retention of nanomotors in the bladder. In addition, we conﬁrm the anti-tumor effect of nanomotor containing the STING agonist (94.2% of inhibition), with recruitment of CD8+ T cells (11.2-fold compared with PBS) and enhanced anti-tumor immune responses in bladder cancer model in female mice. Furthermore, we demonstrate the better anti-tumor effect of nanomotor containing the STING agonist than those of the gold standard Bacille Calmette-Guerin therapy and the antiPD-1 inhibitor pembrolizumab in bladder cancer model. Taken together, the urease-powered nanomotor would provide a paradigm as a next-generation platform for bladder cancer immunotherapy.  \nBladder cancer is the fourth most common cancer in men worldwide and the incidence of bladder cancer is gradually increasing with aging1,2. As a representative symptom of bladder cancer, hematuria allows the early detection of bladder cancer and almost 75% of bladder cancers are diagnosed as a non-muscle invasive bladder cancer (NMIBC)3. The current primary treatment for NMIBC involves the transurethral resection of bladder tumors, followed by the intravesical  \ninstillation of Bacille Calmette-Guerin (BCG). This treatment is widely considered to be the gold standard for intermediate to high risk NMIBC due to its high response rate and capability to reduce the disease progression by activating the immune system of patients. However, BCG fails in about 20−40% of patients during the follow up. Furthermore, BCG treatment is associated with the risk of mycobacterial infection4–7.  \n1Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. 2PHI BIOMED Co., Seocho-gu, Seoul, Korea. 3Department of Urology, Seoul National University College of Medicine, Jongno-gu, Seoul, Korea. 4Department of Urology, Seoul National University Hospital, Jongno-gu, Seoul, Korea. 5CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, Guipúzcoa, Spain. 6Department of Materials Science and Engineering, Pohang University of Science and Technology (POSTECH), Pohang, Gyeongbuk, Korea. 7Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Yuseong-gu, Daejeon, Korea. 8Institució Catalana de Recerca i Estudis Avancats (ICREA), Passeig Lluís Companys 23, Barcelona, Spain. 9These authors contributed equally: Hyunsik Choi, Seung-hwan Jeong.  \n[e-mail:](e-mail: mdrafael@snu.ac.kr)[ mdrafael@snu.ac.kr](e-mail: mdrafael@snu.ac.kr); [gykoh@kaist.ac.kr](gykoh@kaist.ac.kr); [ssanchez@ibecbarcelona.eu](ssanchez@ibecbarcelona.eu); [skhanb@postech.ac.kr](skhanb@postech.ac.kr)  \nSTimulator of INterferon Genes (STING) mediates innate and adaptive immune systems as a signaling molecule which resides in endoplasmic reticulum. Aberrant cytoplasmic exposure","cbCaiij5EQiduUJR","https://ap.wps.com/l/cbCaiij5EQiduUJR","pdf",3610198,16,"English","# Abstract\n## Background and clinical need\n## Design of urease-powered STING nanomotor\n## Characterization and in vivo performance\n## Anti-tumor efficacy and comparisons","[{\"question\":\"Why is intravesical delivery difficult for bladder cancer immunotherapy?\",\"answer\":\"Therapeutic agents have low delivery efficiency because frequent urination clears them and the urothelial glycosaminoglycan layer hinders penetration into the bladder wall.\"},{\"question\":\"What is the main goal of the urease-powered nanomotor in this study?\",\"answer\":\"To enable rapid and efficient delivery of a STING agonist into the bladder wall, improving activation of immune cells within the tumor environment.\"},{\"question\":\"How does the nanomotor perform compared with standard therapies?\",\"answer\":\"The STING agonist nanomotor shows stronger anti-tumor effects than BCG and the anti-PD-1 inhibitor pembrolizumab in a bladder cancer mouse model, including high tumor inhibition and enhanced CD8+ T-cell recruitment.\"}]","Urease-powered nanomotor containing STING agonist for bladder cancer immunotherapy | PDF",1790011321]